L3VLUP
ProSign in

CHRS · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CHRSARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CHRS
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterCHRSARGX
Q3 20203 holders, $86m8 holders, $3.6bn
Q4 20204 holders, $85m7 holders, $4.1bn
Q1 20213 holders, $3.3m8 holders, $4.1bn
Q2 20213 holders, $3.1m9 holders, $4.6bn
Q3 20211 holders, $26k8 holders, $4.5bn
Q4 20214 holders, $95m9 holders, $5.3bn
Q1 20223 holders, $78m8 holders, $5.3bn
Q2 20221 holders, $10k13 holders, $6.5bn
Q3 20222 holders, $59m14 holders, $5.3bn
Q4 20221 holders, $13k13 holders, $5.5bn
Q1 20232 holders, $778k13 holders, $5.9bn
Q2 20231 holders, $2.1m18 holders, $6.6bn
Q3 20233 holders, $2.2m21 holders, $8.7bn
Q4 20232 holders, $3.6m17 holders, $6.3bn
Q1 20242 holders, $3.0m13 holders, $6.8bn
Q2 20241 holders, $558k14 holders, $7.9bn
Q3 2024none listed holders, n.a.13 holders, $10.7bn
Q4 2024none listed holders, n.a.14 holders, $12.3bn
Q1 2025none listed holders, n.a.17 holders, $11.8bn
Q2 2025none listed holders, n.a.18 holders, $10.8bn
Q3 2025none listed holders, n.a.16 holders, $13.8bn
Q4 2025none listed holders, n.a.16 holders, $14.8bn
Q1 2026none listed holders, n.a.11 holders, $12.3bn
Q2 2026none listed holders, n.a.14 holders, $15.0bn
CHRS

Coherus Oncology Inc

Holders
0
Reported value
$0
Buyers
11
Sellers
4

Breadth +7 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
11
Reported value
$12.3bn
Buyers
15
Sellers
14

Breadth +1 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2026

Among the 11 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only CHRS (0)

None.

Only ARGX (11)

AllianceBernstein LP, Artisan Partners LP, Capital World Investors, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, T. Rowe Price Associates Inc, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →